|
ScinoPharm Taiwan is a pharmaceutical company specializing in the development and manufacturing of high-barrier active pharmaceutical ingredients (APIs) and drug products. The company provides integrated CDMO services, covering process development, clinical sample preparation, and commercial-scale production for small molecules and peptides. Its therapeutic focus includes oncology, hematology, central nervous system disorders, cardiovascular diseases, orphan drugs, and metabolic diseases, with active development in GLP-1 related products. ScinoPharm operates FDA- and cGMP-compliant facilities, including a sterile injectable plant, and serves global clients, including top-tier patented and generic pharmaceutical companies. Key subsidiaries include SciAnda (Changshu) Pharmaceutical Ltd., ScinoPharm (Kunshan) Biotech Ltd., and ScinoPharm Biotech Ltd. The company was established in 1997 and has passed multiple FDA inspections with zero deficiencies. Summarised from the company's own disclosures, fiscal year ended Oct 2026 |
Industry Drug Manufacturers - Specialty & Generic | Homepage scinopharm.com |
| Sector Healthcare | IR page scinopharm.com/investor | |
|
Tags
active pharmaceutical ingredients, drug products, cdmo services, oncology, hematology, central nervous system, cardiovascular, orphan drugs, metabolic diseases, glp-1, small molecules, peptides, SciAnda (Changshu) Pharmaceutical Ltd., ScinoPharm (Kunshan) Biotech Ltd., ScinoPharm Biotech Ltd.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | NT$ 14.229B |
| Market cap (USD) | $ 431.887M |
| P/E | 900.00 |
| PEG | — |
| P/BV | 1.27 |
| P/S | 4.68 |
| P/OCF | 18.95 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 1.3% |
| ROI | 1.3% |
| ROIC | 0.96% |
| Profit margin | 4.3% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -27.1% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -56.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.163B | 3.406B | 3.186B | 3.264B | 2.762B | 3.083B | 2.893B | 3.524B | 3.516B | 4.031B | 3.955B | 4.098B | 5.088B | 4.573B | 3.954B | 3.891B |
| Net profit | 136.951M | 339.35M | 287.056M | 353.216M | 243.471M | 282.067M | 216.656M | 442.978M | 422.367M | 658.693M | 634.965M | 484.143M | 1.273B | 1.17B | 959.355M | 1.04B |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 16.75 | 22.05 | 26.4 | 25.45 | 24.65 | 28.85 | — | — | — | — | — | — | — | — | — | — |
| Price performance 12m | -0.24 | -0.16 | 0.04 | 0.03 | -0.15 | — | — | — | — | — | — | — | — | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding ScinoPharm Taiwan, Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.01% | 26,000 | $ 15.501K | Nov 16, 2026 |
| DEXC | 0.00% | 22,000 | $ 13.112K | Nov 12, 2026 |
| DFEV | 0.00% | 90,000 | $ 53.64K | Nov 12, 2026 |
| DFEM | 0.00% | 301,000 | $ 179.398K | Nov 12, 2026 |
| DFAX | 0.00% | 182,000 | $ 108.473K | Nov 12, 2026 |
| DFAE | 0.00% | 98,000 | $ 58.409K | Nov 12, 2026 |
| AVEM | 0.00% | 2,000 | $ 1,192.37 | Nov 16, 2026 |
| AVSE | 0.00% | 1,000 | $ 596.19 | Nov 16, 2026 |



